Literature DB >> 9935152

Reduction of syndecan-1 mRNA in cervical-carcinoma cells is involved with the 3' untranslated region.

K Nakanishi1, N Yoshioka, K Oka, A Hakura.   

Abstract

Syndecan-1 is a transmembrane proteoglycan expressed predominantly in epithelial cells. Studies with immunohistochemistry have shown that syndecan-1 expression is reduced in carcinoma derived from human epidermis. Here we show that syndecan-1 mRNA, which is abundant in human primary keratinocyte (HK) and HaCaT spontaneous immortalized keratinocyte, is decreased in cervical-carcinoma cell lines. Further, in relation to a long and well-conserved 3' untranslated region (3' UTR) of syndecan-1 cDNA, we examined whether 3' UTR is involved with syndecan-1-mRNA reduction in cervical-carcinoma cells. A stable transfection experiment showed that addition of the 3' UTR does not affect expression in HaCaT, but that syndecan-1 cDNA containing the 3' UTR is not expressed efficiently selectively in cervical-carcinoma cell lines. The transient assay with CAT reporter plasmids linking the 3' UTR confirmed this, and indicated that the 3' end of the 3' UTR (nt 2285-2410) is required to influence expression in cervical-carcinoma cells. Further excessive expression of syndecan-1 suppressed growth in cervical-carcinoma cells. These results demonstrate that the reduction of syndecan-1 mRNA involved with the 3' untranslated region gives growth advantage to cervical-carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935152     DOI: 10.1002/(sici)1097-0215(19990209)80:4<527::aid-ijc8>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia.

Authors:  Gábor Sobel; István Szabó; Csilla Páska; András Kiss; Ilona Kovalszky; Anna Kádár; Ferenc Paulin; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

Review 2.  Syndecans in tumor cell adhesion and signaling.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  Reprod Biol Endocrinol       Date:  2004-01-07       Impact factor: 5.211

Review 3.  Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis.

Authors:  Hao-Tang Wei; Er-Na Guo; Bao-Guo Dong; Li-Sheng Chen
Journal:  BMC Gastroenterol       Date:  2015-10-30       Impact factor: 3.067

4.  Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.

Authors:  M Fujiya; J Watari; T Ashida; M Honda; H Tanabe; T Fujiki; Y Saitoh; Y Kohgo
Journal:  Jpn J Cancer Res       Date:  2001-10

5.  Aberrant Expression of Syndecan-1 in Cervical Cancers.

Authors:  Katalin Karászi; Renáta Vigh; Miklós Máthé; Alexandra Fullár; Lászlóné Oláh; Tibor Füle; Zoltán Papp; Ilona Kovalszky
Journal:  Pathol Oncol Res       Date:  2020-05-10       Impact factor: 3.201

Review 6.  Syndecans as modulators and potential pharmacological targets in cancer progression.

Authors:  Despoina Barbouri; Nikolaos Afratis; Chrisostomi Gialeli; Demitrios H Vynios; Achilleas D Theocharis; Nikos K Karamanos
Journal:  Front Oncol       Date:  2014-02-03       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.